CoChat

Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population

Open access
So, Jimmy Bok Yan, Kapoor, Ritika, Zhu, Feng, Koh, Calvin, Zhou, Lihan, Zou, Ruiyang, Tang, Yew Chung, Goo, Patrick C K, Rha, Sun Young, Chung, Hyun Cheol, Yoong, Joanne, Yap, Celestial T, Rao, Jaideepraj, Chia, Chung-King, Tsao, Stephen, Shabbir, Asim, Lee, Jonathan, Lam, Kong-Peng, Hartman, Mikael, Yong, Wei Peng, Too, Heng-Phon, Yeoh, Khay-Guan · 2021 · Gut
Cited by 208

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Objective: An unmet need exists for a non-invasive biomarker assay to aid gastric cancer diagnosis. We aimed to develop a serum microRNA (miRNA) panel for identifying patients with all stages of gastric cancer from a high-risk population. Design: We conducted a three-phase, multicentre study comprising 5248 subjects from Singapore and Korea. Biomarker discovery and verification phases were done through comprehensive serum miRNA profiling and multivariant analysis of 578 miRNA candidates in retrospective cohorts of 682 subjects. A clinical assay was developed and validated in a prospective cohort of 4566 symptomatic subjects who underwent endoscopy. Assay performance was confirmed with histological diagnosis and compared with Helicobacter pylori (HP) serology, serum pepsinogens (PGs), ‘ABC’ method, carcinoembryonic antigen (CEA) and cancer antigen 19–9 (CA19-9). Cost-effectiveness was analysed using a Markov decision model. Results: We developed a clinical assay for detection of gastric cancer based on a 12-miRNA biomarker panel. The 12-miRNA panel had area under the curve (AUC)=0.93 (95% CI 0.90 to 0.95) and AUC=0.92 (95% CI 0.88 to 0.96) in the discovery and verification cohorts, respectively. In the prospective study, overall sensitivity was 87.0% (95% CI 79.4% to 92.5%) at specificity of 68.4% (95% CI 67.0% to 69.8%). AUC was 0.848 (95% CI 0.81 to 0.88), higher than HP serology (0.635), PG 1/2 ratio (0.641), PG index (0.576), ABC method (0.647), CEA (0.576) and CA19-9 (0.595). The number needed to screen is 489 annually. It is cost-effective for mass screening relative to current practice (incremental cost-effectiveness ratio=US$44 531/quality-of-life year). Conclusion: We developed and validated a serum 12-miRNA biomarker assay, which may be a cost-effective risk assessment for gastric cancer. Trial registration number: This study is registered with ClinicalTrials.gov (Registration number: NCT04329299).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2020-322065

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 208

Metadata

Authors
So, J. B. Y., Kapoor, R., Zhu, F., Koh, C., Zhou, L., Zou, R., Tang, Y. C., Goo, P. C. K., Rha, S. Y., Chung, H. C., Yoong, J., Yap, C. T., Rao, J., Chia, C.-K., Tsao, S., Shabbir, A., Lee, J., Lam, K.-P., Hartman, M., Yong, W. P., Too, H.-P., & Yeoh, K.-G.
Venue
Gut
Publisher
BMJ
Published
2020-10-07
Volume
70
Issue
5
Pages
829-837
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W3092368475
Cited by
208
References
4
FWCI
6.97
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. https://app.cochat.ai/papers/10.1136/gutjnl-2020-322065
The paper
So, J. B. Y., Kapoor, R., Zhu, F., Koh, C., Zhou, L., Zou, R., Tang, Y. C., Goo, P. C. K., Rha, S. Y., Chung, H. C., Yoong, J., Yap, C. T., Rao, J., Chia, C.-K., Tsao, S., Shabbir, A., Lee, J., Lam, K.-P., Hartman, M., . . . Yeoh, K.-G. (2021). Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. Gut. https://doi.org/10.1136/gutjnl-2020-322065

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.